Update!
$PDS Biotechnology(PDSB.US$ PDS Biotech Announces Interim 24-Month Survival Rate of 74% in Immune Checkpoint Inhibitor Naïve Head and Neck Cancer Patients Treated With PDS0101 in Combination With KEYTRUDA (Pembrolizumab)![]()
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
